Log in to search using one of your social media accounts:


Association of urinary and plasma DNA in early breast cancer patients and its links to disease relapse

ConclusionUrinary DNA offers a unique opportunity to glimpse upon dynamic changes in early breast cancer. Our results demonstrated good correlation to plasma DNA and post monitoring of cancer patients to identify individuals susceptible to a high risk of relapse. This potentially allows for early intervention such as adjuvant chemotherapy to be administered to better manage these patients.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

In conclusion, we identified no SNPs significantly associated with NAC. The observation, in a hypothesis-generating GWAS, of an SNP in CDKAL1 associated with pCR in the bevacizumab arm of both B-40 and GeparQuinto requires further validation and study.
Source: Pharmacogenetics and Genomics - Category: Genetics & Stem Cells Tags: Short Communication Source Type: research
Authors: Ma G, Huang H, Li M, Li L, Kong P, Zhu Y, Xia T, Wang S Abstract Neoadjuvant chemotherapy (NCT) is the standard treatment for locally advanced breast cancer (LABC). Pathological complete response (pCR) is commonly used as a valid predictor of NCT long-term outcomes. Blood-based tumor biomarkers have the potential to predict response to NCT at early stage non-invasively. We believed plasma CCL5 could be a potential marker to predict NCT of LABC. Its efficiency and possible mechanism was studied in this work. Human Cytokine Antibody Microarray was applied to screen different cytokine concentration in plasma ...
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
ConclusionOur results confirm the possible role of theLAPTM4B gene in anthracycline resistance in HR − breast cancer. AnalyzingLAPTM4B copy number pattern may support future treatment decision.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Authors: Li J, Gao W, Yu B, Wang F, Wang L Abstract PURPOSE: To investigate multi-slice spiral CT (MSCT) imaging with breast cancer chemotherapy and the correlation between MSCT and breast cancer-specific gene 1 (BCSG1). METHODS: 86 patients with breast cancer were enrolled from January 2016 to May 2017. All of them were treated with neoadjuvant chemotherapy, and underwent MSCT scan before and after treatment to evaluate the efficacy of chemotherapy. The expression of BCSG1 in tumor tissue was detected by immunohistochemistry and the correlation between CT results and BCSG1 was analyzed. RESULTS: MSCT evalu...
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
When a patient has a confirmed diagnosis of invasive breast cancer, the patient may receive chemotherapy ahead of surgery. This is called neoadjuvant therapy and is used to shrink tumors before they are removed surgically. It also treats cancer that has spread (metastasized). Imaging tests before and during neoadjuvant treatment can help guide treatment decisions.
Source: Journal of the American College of Radiology : JACR - Category: Radiology Authors: Tags: Appropriate use criteria Source Type: research
CONCLUSION: PLAC-B as neoadjuvant treatment of this subpopulation with TNBC and ER/PR+ patients is effective and safe. Further studies are necessitated. PMID: 29744672 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Clin Drug Investig Source Type: research
ConclusionPLAC-B as neoadjuvant treatment of this subpopulation with TNBC and ER/PR+ patients is effective and safe. Further studies are necessitated.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
Abstract Objectives: Pathologic complete response (pCR) rate after neoadjuvant chemotherapy was compared between 141 estrogen receptor (ER)-negative (43%), 41 low ER+ (13%), 47 moderate ER+ (14%), and 98 high ER+ (30%) tumors. Methods: Human epidermal growth factor receptor 2-positive cases, cases without semiquantitative ER score, and patients treated with neoadjuvant endocrine therapy alone were excluded. Results: The pCR rate of low ER+ tumors was similar to the pCR rate of ER- tumors (37% and 26% for low ER and ER- respectively, P = .1722) but significantly different from the pCR rate of moderately E...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Am J Clin Pathol Source Type: research
After an overview of the principles of fludeoxyglucose-PET/computed tomography (CT) in breast cancer, its advantages and limits to evaluate treatment response are discussed. The metabolic information is helpful for early assessment of the response to neoadjuvant chemotherapy and could be used to monitor treatment, especially in aggressive breast cancer subtypes. PET/CT is also a powerful method for early assessment of the treatment response in the metastatic setting. It allows evaluation of different sites of metastases in a single examination and detection of a heterogeneous response. However, to use PET/CT to assess resp...
Source: PET Clinics - Category: Radiology Authors: Source Type: research
Conclusion: The results of the study confirm the high pCR rate in BRCA1-positive breast cancer after platinum-based neoadjuvant chemotherapy. Larger randomized studies and longer follow-up times are necessary to evaluate the role of platinum-based therapies in BRCA1-positive breast cancer. PMID: 29719582 [PubMed]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Hered Cancer Clin Pract Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study